The University Of Manitoba

The University of Manitoba, a foreign government-controlled Canadian institution of higher learning based in Winnipeg, Manitoba, operates as a federal grant recipient conducting biomedical and environmental research for U.S. federal agencies, with 63% of recent awards as prime recipient and 37% as sub-recipient on grants led by U.S. research institutions.

The university's federal footprint concentrates heavily in health research. The top five funding agencies account for 48% of awards by count, led by the National Institute of Allergy and Infectious Diseases (10 awards), the Centers for Disease Control and Prevention (9 awards), and the CDC Pittsburgh office (7 awards, $29.7 million combined potential value). The CDC Pittsburgh office dominates the potential-value ranking at $29.7 million across seven awards; the dollar concentration diverges sharply from volume concentration—NIAID leads by award count but represents a small fraction of dollar value. The university holds seats on two CDC indefinite delivery vehicles: Indefinite Delivery Contract 200200100083 (7 task orders, $175 thousand combined potential value) and Indefinite Delivery Contract HHSD200200100083I (5 task orders, $3.3 million combined potential value).

Recent prime-grant work spans neuroscience, military medicine, and environmental toxicology. The National Institute of Mental Health awarded $191,910 (July 1, 2026) for an electroencephalography study of auditory predictive learning abnormalities in schizophrenia, running through June 30, 2028 (CFDA 93.242). The Defense Health Agency funded a $249,823 project grant (September 1, 2025 through August 31, 2027) titled "Polygenicity of Brain and Physical Reserve in Multiple Sclerosis" (CFDA 12.420). The National Institute of Child Health and Human Development awarded a multi-omics human milk composition study (August 12, 2022, running through July 31, 2027). The University of Manitoba also serves as recipient on a Department of Interior Fish and Wildlife Service Region 7 cooperative agreement (April 30, 2024) studying polycyclic aromatic compound concentrations in common eider eggs across 18 breeding sites in eastern Canada to establish baseline pollution exposure for marine bird species and Inuit and First Nations food safety.

In sub-recipient roles, the university participates in grant teams led by research institutions including University of Pennsylvania, University of North Carolina at Chapel Hill, University of Kansas, Case Western Reserve University, Cedars-Sinai Medical Center, and Rush University Medical Center, typically providing laboratory facilities, clinical recruitment, data analysis, or site coordination services. Recent sub-award activity includes participation in HIV susceptibility research, multiple sclerosis progression genetics studies, sexually transmitted infection microbiome studies, and blood-brain barrier therapeutic permeability research.

Activity has fluctuated—four awards in 2021, two in 2022, then ten each in 2024 and 2025, with six awards in 2026—with only three awards facing ultimate completion within the next twenty-four months. Research output concentrates in NAICS Colleges, Universities, and Professional Schools and professional scientific services, with primary PSC coding under R&D Social Services and health research categories. Combined obligated dollars ($53.9 million) exceed combined potential value ($31 million) by 174%, indicating prior-year obligations from ongoing multi-year grants. The university's performance location includes a primary facility at 2323 Riverside Drive, Ottawa, Ontario, with research spanning domestic U.S. sites and international fieldwork in India and Atlantic Canada.